Company

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio
Alcon LaboratoriesNeurotech Pharmaceuticals

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

Alcon Laboratories, Inc. (NYSE: ALC), the US‑based eye care company, announced that it has acquired Neurotech Pharmaceuticals, Inc., a developer of innovative cell therapies for chronic and neurodegenerative eye diseases,…

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Cutia Therapeutics Expands CU-20401 Licensing Collaboration with Rejuven Dermaceutical Beyond Asia – Recombinant Mutant Collagenase for Localized Fat Reduction Goes Global

Sihuan Pharmaceutical's PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Sihuan Pharmaceutical’s PCL Facial Filler and L‑Carnosine Skin Booster Win Hong Kong Market Approval – Meiyan Space Aesthetics Duo Expands Beyond Mainland China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Ascentage PharmaCDE

Ascentage Pharma and Haisco Secure CDE SPARK Inclusion for Pediatric Oncology Candidates – APG‑115 and HSK42360 Target High‑Unmet‑Need Childhood Cancers

AIOTCMKTS: RHHBY

Roche Deploys 2,176 NVIDIA GPUs in Global AI Factory – Largest Pharma GPU Footprint Expands to 3,500+ Blackwell Units

BeOne Medicines

BeOne Innovation Center and Voyagers Capital Launch Fund – Early-Stage Drug Investment Vehicle Targets Guangzhou Biotech

Sino Biopharm's TRD221 Wins NMPA Approval – Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition
Clinical trial approval / initiationHKG: 1177

Sino Biopharm’s TRD221 Wins NMPA Approval – Novel Polysaccharide Drug Targets Osteoarthritis via Complement Inhibition

Show More